Studies testing ONC201 and/or TR compounds in breast cancer models collectively show that ClpP agonists exert a significant anti-proliferative effect accompanied with ISR and cell cycle arrest, rather than inducing apoptosis [58,268,270,298,299,301,302,304,306]. Here, CLPP is linked to breast carcinoma.